论文部分内容阅读
目的研究阿地溴铵对慢性阻塞性肺疾病(COPD)患者肺功能及生存质量的安全性及有效性。方法检索Pubmed database、Embase database(using ovid)、medline及Cochrane Controlled Trials Registry database,选取随机临床试验(RCTs)研究,对阿地溴铵进行系统性评价。结果阿地溴铵能显著改善患者的一秒用力呼气容积(FEV1)、提高运动耐力、缓解症状和减轻患者急性加重期入院的频率及急救药品的使用。结论阿地溴铵FEV1达峰时间更快,能更大程度减少患者呼吸困难和夜间发作症状,每日两次的吸入剂量使患者更加耐受,并降低治疗费用,减轻患者经济负担。
Objective To study the safety and efficacy of abidinium bromide in lung function and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods We searched Pubmed database, Embase database (using ovid), medline and Cochrane Controlled Trials Registry database. Randomized clinical trials (RCTs) were conducted to evaluate the clinical evaluation of ABI. Results Abidium bromide significantly improved the patient’s forced expiratory volume in one second (FEV1), increased exercise tolerance, relieved symptoms and reduced the frequency of hospital admissions and the use of first-aid medicines in acute exacerbations. Conclusions Adefloxacin has a faster peak time of FEV1, which can reduce the difficulty of breathing and nocturnal onset symptoms to a greater extent. The twice-daily inhaled dose can make patients more tolerated, reduce the cost of treatment and reduce the financial burden on patients.